NCT03794349 2026-02-18Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory NeuroblastomaChildren's Oncology GroupPhase 2 Active not recruiting94 enrolled 14 charts
NCT04301843 2026-02-03Eflornithine (DFMO) and Etoposide for Relapsed/Refractory NeuroblastomaMilton S. Hershey Medical CenterPhase 2 Recruiting131 enrolled
NCT02395666 2024-08-06Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in RemissionMilton S. Hershey Medical CenterPhase 2 Completed140 enrolled 14 charts 1 FDA